GL701: GNLB began a second Phase III trial

Genelabs Technologies Inc. (GNLB), Redwood City, Calif. Product: GL701, DHEA (dehydroepiandrosterone) Indication: Lupus Status: GNLB began a second Phase III trial in which it plans to enroll 300 wom...